Publications by authors named "T Eggert"
Article Synopsis
- AMG 193 is a drug that targets tumor cells lacking the MTAP gene, which is deleted in approximately 10%-15% of solid tumors, and has shown promise in selectively killing these cancer cells through synthetic lethality.* -
- The phase I clinical study involved 80 patients with advanced solid tumors, testing varying doses of AMG 193 to assess safety, tolerability, and preliminary effectiveness; common side effects included nausea, fatigue, and vomiting.* -
- Results indicated a maximum tolerated dose of 1200 mg, with a 21.4% objective response rate observed in patients receiving effective doses, suggesting activity against multiple tumor types including lung and pancreatic cancers.*
In this pilot study, the authors investigated the preliminary effectiveness of the digital lifestyle intervention, actensio (mementor DE GmbH), in treating arterial hypertension. Adults with arterial hypertension were randomly assigned to an intervention group (actensio + standard care) or a control group (waiting list + standard care) in a 1:1 ratio. Primary and secondary endpoints were assessed at baseline (t0) and 3 months post-randomization (t1).
View Article and Find Full Text PDFPurpose: The cardiorespiratory polysomnography (PSG) is an expensive and limited resource. The Sleepiz One + is a novel radar-based contactless monitoring device that can be used e.g.
View Article and Find Full Text PDFBackground: The adverse events (AEs) after a Coronavirus disease 2019 (Covid-19) Pfizer-Biotech mRNA vaccination present a medical and epidemiological issue of increasing interest. Headache is the most frequent neurological adverse effect and generally the third most common adverse event after a Covid-19 vaccination, but only a few studies focus on the link between headache and other AEs after vaccination. This study aims to investigate the correlation between headaches and Covid-19 vaccination, as well as the possible links between headaches and other AEs after Covid-19 vaccination, thereby helping the management of AEs and avoiding further occurrences.
View Article and Find Full Text PDFArticle Synopsis
- A first-in-human study was conducted to evaluate the safety and efficacy of acapatamab, a bispecific T-cell engager targeting metastatic castration-resistant prostate cancer (mCRPC).
- 133 patients participated, receiving varying doses of acapatamab; the most common side effect was cytokine release syndrome (CRS), noted in a large majority, particularly during the first treatment cycle.
- Preliminary results showed some antitumor activity, with 30.4% of patients experiencing confirmed PSA responses, though the overall durable activity was limited and further evaluation is needed.